Search Results 2401-2410 of 21881 for platelets

1. Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast - Mayo Clinic

   Platelets ≥ 100,000/microliter;; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN);; AST (SGOT)/ALT (SGPT) ≤ 1.5 × ULN;; Creatinine ≤ 1.5 x ...

2. Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma - Mayo Clinic

   Platelet count ≥ 75,000/mm3. Adequate hepatic and renal function obtained ≤14 days prior to registration as demonstrated by: Alanine and Aspartate ...

3. Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery - Mayo Clinic

   Platelet count >= 100,000/mm^3 (100 x 10^9 /L); Hemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L) without transfusion or erythropoietin (EPO) dependency (within ...

4. Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients with Refractory or Relapsed Indolent Non-Hodgkin Lymphoma - Mayo Clinic

   Platelet count ≥ 100,000/mL; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) OR, if total bilirubin is > 1.5 x ULN, the direct bilirubin ...

5. Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer - Mayo Clinic

   Platelet count ≥ 100 x 10^9/L; Hemoglobin ≥ 8.0 g/dL; Serum alanine aminotransferase ([ALT]; serum glutamate-pyruvate transferase [SGPT]), or serum ...

6. A Study to Evaluate the Effectiveness and Safety of Vedolizumab to Treat Chronic Pouchitis - Mayo Clinic

   Platelet count <100 × 10^9/L or > 1200 × 10^9/L;; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × the upper limit of normal (ULN); ...

7. A Study of MK-1026 in Patients with Selected Hematologic Malignancies - Mayo Clinic

   Platelet count ≥ 50,000/µL;; Absolute neutrophil count (ANC) ≥ 1000/µL;; Hemoglobin (Hgb) ≥ 8.0 g/dL, stable for ≥ 1 week. For men and women of child ...

8. Doxorubicin Hydrochloride, Cyclophosphamide, And Paclitaxel With Or Without Bevacizumab In Treating Patients With Lymph Node-Positive Or High-Risk, Lymph Node-Negative Breast Cancer - Mayo Clinic

   Platelet count ≥ 100,000/mm^3; Total bilirubin ≤ 1.5 mg/dL; Aspartate aminotransferase (AST) ≤ 2 times upper limit of normal(ULN); Serum creatinine ≤ 1.5 ...

9. A Study To Evaluate APG2575 Combined With Novel Therapeutic Regimens To Treat Subjects With Relapsed Or Refractory Multiple Myeloma And Immunoglobulin Light Chain Amyloidosis - Mayo Clinic

   Platelet count ≥ 50 x 10^9/L without transfusion support within 7 days of the first dose of study drug. Adequate hepatic and renal function defined as: AST ...

10. A Study to Evaluate the Safety, Effectiveness and Microbiological Response of Orally Administered ABI-M201 in Subjects with Mildly-to-Moderately Active Ulcerative Colitis with Ongoing Mesalamine Treatment - Mayo Clinic

    Hemoglobin concentration < 9 g/dL, WBC below 3,000/cm3 or platelets below 100,000/cm3. Chronic kidney disease with an estimated glomerular filtration rate ...